Home 5 Clinical Diagnostics Insider 5 Diagnostics Pipeline: FDA Opens Path for Blood Tests Assessing Genetic Cancer Risk

Diagnostics Pipeline: FDA Opens Path for Blood Tests Assessing Genetic Cancer Risk

by | Jan 2, 2024 | Clinical Diagnostics Insider, Dx Pipeline-lir, FDA-lir

First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.

Subscribe to Clinical Diagnostics Insider to view

Start a Free Trial for immediate access to this article